Patents by Inventor William Raestetter

William Raestetter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Clinical Parameters for Determining Hematologic Toxicity Prior to Radioimmunotherapy
    Publication number: 20070148714
    Abstract: New clinical parameters are reported which may serve as predictors of the hematological toxicity associated with therapeutic radiolabeled antibodies, particularly those antibodies which target lymphoma cells which have a tendency to localize to the bone marrow.
    Type: Application
    Filed: February 27, 2007
    Publication date: June 28, 2007
    Inventors: William Raestetter, Christine White
  • Clinical parameters for determining hematologic toxicity prior to radioimmunotherapy
    Patent number: 7195750
    Abstract: New clinical parameters are reported which may serve as predictors of the hematological toxicity associated with therapeutic radiolabeled antibodies, particularly those antibodies which target lymphoma cells which have a tendency to localize to the bone marrow.
    Type: Grant
    Filed: July 16, 2002
    Date of Patent: March 27, 2007
    Assignee: Biogen IDEC Inc.
    Inventors: William Raestetter, Christine A. White
  • Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy
    Patent number: 6451284
    Abstract: New clinical parameters are reported which may serve as predictors of the hematological toxicity associated with therapeutic radiolabeled antibodies, particularly those antibodies which target lymphoma cells which have a tendency to localize to the bone marrow.
    Type: Grant
    Filed: July 26, 2000
    Date of Patent: September 17, 2002
    Assignee: IDEC Pharmaceuticals Corporation
    Inventors: William Raestetter, Christine A. White